(PublicWire) — Neurologix, Inc. (OTCBB: NRGX), a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced that Reginald L. Hardy has been appointed as a director of the company to fill a vacancy on its Board of Directors. Mr. Hardy has extensive experience in the pharmaceutical and drug industries and currently serves as President of Concordia Pharmaceuticals, Inc., an anti-cancer drug development company that he founded.
Neurologix recently announced completion of all planned surgeries in its Phase 2 clinical trial of the Company’s gene transfer approach to the treatment of advanced Parkinson’s disease and expects to announce initial efficacy results from such trial in the middle of this year.
Dr. Martin J. Kaplitt, the company’s Chairman, stated that “Reg’s significant experience in the drug and pharmaceutical industries, together with his management and business background, will be invaluable to the company as we prepare for a Phase 3 pivotal trial for our Parkinson’s product.” Mr. Hardy’s initial term will expire at the Company’s 2010 Annual Meeting of Stockholders, and he has been nominated for election for another term at the 2010 Annual Meeting of Stockholders.
Neurologix, Inc. (OTCBB: NRGX) is a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and central nervous system. Neurologix’s therapeutic approach is built upon the groundbreaking research of its scientific founders and advisors, whose accomplishments have formed the foundation of gene therapy for neurological illnesses. The Company’s current programs address such conditions as Parkinson’s disease, epilepsy and Huntington’s disease, all of which are large markets not adequately served by current therapeutic options. For more information, please visit the Neurologix website by clicking here.